Meristem Family Wealth LLC bought a new position in GlaxoSmithKline plc (NYSE:GSK) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 5,018 shares of the pharmaceutical company’s stock, valued at approximately $201,000.
Other hedge funds have also recently modified their holdings of the company. D Orazio & Associates Inc. lifted its position in GlaxoSmithKline by 200.0% in the first quarter. D Orazio & Associates Inc. now owns 600 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 400 shares during the period. Berman Capital Advisors LLC lifted its position in GlaxoSmithKline by 58.1% in the second quarter. Berman Capital Advisors LLC now owns 656 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the period. Financial Gravity Wealth Inc. lifted its holdings in shares of GlaxoSmithKline by 62.7% during the second quarter. Financial Gravity Wealth Inc. now owns 799 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 308 shares during the period. Princeton Global Asset Management LLC bought a new position in shares of GlaxoSmithKline during the first quarter valued at $37,000. Finally, Reilly Financial Advisors LLC lifted its holdings in shares of GlaxoSmithKline by 36.7% during the first quarter. Reilly Financial Advisors LLC now owns 950 shares of the pharmaceutical company’s stock valued at $36,000 after acquiring an additional 255 shares during the period. 11.30% of the stock is owned by hedge funds and other institutional investors.
In other GlaxoSmithKline news, Director Plc Glaxosmithkline bought 385,714 shares of the stock in a transaction dated Tuesday, May 28th. The stock was bought at an average cost of $14.00 per share, for a total transaction of $5,399,996.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 10.00% of the company’s stock.
A number of research analysts have issued reports on GSK shares. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Tuesday, August 13th. Morgan Stanley reissued an “underweight” rating on shares of GlaxoSmithKline in a report on Monday, June 17th. Zacks Investment Research cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Thursday, April 25th. Finally, Cowen reissued a “hold” rating and set a $45.00 price objective on shares of GlaxoSmithKline in a report on Monday, June 10th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $41.79.
Shares of NYSE GSK traded up $0.38 during midday trading on Friday, reaching $41.36. 118,791 shares of the company traded hands, compared to its average volume of 2,410,493. The firm has a market cap of $101.65 billion, a PE ratio of 13.08, a PEG ratio of 1.96 and a beta of 0.71. The stock’s 50-day simple moving average is $40.89 and its 200-day simple moving average is $40.49. GlaxoSmithKline plc has a 12 month low of $36.41 and a 12 month high of $42.47. The company has a debt-to-equity ratio of 7.86, a quick ratio of 0.48 and a current ratio of 0.71.
GlaxoSmithKline (NYSE:GSK) last announced its earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.14. GlaxoSmithKline had a return on equity of 175.45% and a net margin of 13.84%. The company had revenue of $10.04 billion during the quarter, compared to analyst estimates of $9.55 billion. On average, equities research analysts expect that GlaxoSmithKline plc will post 2.91 EPS for the current year.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Story: Outstanding Shares, Buying and Selling Stocks
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.